Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies and SRI International Announce Licensing Deal

Published: Tuesday, December 11, 2012
Last Updated: Tuesday, December 11, 2012
Bookmark and Share
Companies to offer laboratory research customers a package that combines Agilent's solutions with SRI International's complete BioCyc Pathway Database Collection.

The integrated package will allow scientists to access, combine, visualize and analyze biological data sets across multiple "omics" experiments (genomics, transcriptomics, proteomics and metabolomics).

"We are pleased to join forces with SRI to provide this advanced product offering," said Nick Roelofs, president of Agilent's Life Sciences Group. "By combining SRI's rich BioCyc pathway content with our fully-integrated laboratory technologies, we are providing researchers with a complete solution for designing more informed experiments, free of the cumbersome technical challenges of traditional multi-omics research. We chose to work with SRI because of the company's breadth of coverage of organisms and excellent curation."

The new software package will enable researchers to display biological pathway data generated by Agilent's suite of instruments, software and reagents. Agilent solutions include microarrays and next-generation sequencing technology, as well as LC/MS, GC/MS, ICP/MS and NMR systems. Agilent is the sole global provider of world-class instruments, consumables and software for all four "omics" disciplines.

"SRI's databases in the BioCyc Pathway collection will offer Agilent customers the high level of curation needed to accurately interpret their large-scale datasets," said Peter Karp, Ph.D., director of the Bioinformatics Research Group at SRI International. "Our EcoCyc and MetaCyc databases have been curated from 23,000 and 35,000 publications, respectively. Along with other BioCyc databases, they help speed research in myriad domains, including biofuels, agroscience, pharmaceuticals and consumer products."

SRI's BioCyc is a collection of 2,038 Pathway/Genome Databases including 497 complete bacterial genomes from the Human Genome Microbiome Project. Each of the databases in the collection describes the genome and metabolic pathways of a single organism. SRI continues to expand the BioCyc collection with new types of data, curation, genomes and associated pathway predictions.

"Researchers are excited about the extraordinary capabilities they will have with this pathway-driven technology," said Steven Fischer, Agilent's marketing manager for metabolomics and proteomics. "Some of them, for example, may be doing genomics experiments and then realize that their next step should really be a metabolomics experiment. Either way, Agilent's comprehensive suite of integrated technologies provides the hardware, software and consumables required to complete multiple cycles of experiments in multiple disciplines. As each experiment informs the next, they can quickly redesign, collect, measure and analyze new sets of data at a much faster rate than ever before."

Agilent's combined hardware/software and informatics solutions are fueling the next generation of pathway-centric multi-omics research and yielding valuable information about drug responses, drug resistance, diagnostic markers and fundamental disease/toxicity pathways.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Dako Announces CE Mark for Companion Diagnostic
Dako has announced the CE Mark certification for use of PD-L1, a companion diagnostic to Merck's anti-PD-1 immunotherapy Keytruda.
Thursday, August 04, 2016
Agilent to Acquire iLab Solutions
Companies have announced they have signed a definitive agreement under which Agilent will acquire substantially all of the assets of iLab, the market leader in cloud-based solutions for core laboratory management.
Wednesday, June 29, 2016
Agilent, Eurofins Genomics Collaborate
Agilent plans to offer custom components and an assembled plasmid service for Agilent’s SureVector next-generation cloning kits through a collaboration with Eurofins.
Monday, March 14, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Agilent Invests $80M in Lasergen
Company has announced that it has invested $80 million in Lasergen, with innovative next-generation sequencing technology for clinical applications.
Friday, March 11, 2016
Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics
Company has announced a program that gives biologists conducting functional genomics research early access to a potential new resource.
Saturday, February 13, 2016
Agilent Technologies and 10x Genomics Announce Collaboration
Company has announced collaboration to develop a premium exome that provides a streamlined workflow for 10x Genomics'Chromium platform.
Friday, February 12, 2016
Agilent Wins Award for Innovation in LC
Dual-needle technology enhances speed, flexibility.
Thursday, January 28, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Signs Agreement with Thermo Fisher Scientific
Agreement to exchange instrument controls to improve the productivity and user experience.
Thursday, November 12, 2015
Agilent Completes Acquisition of Seahorse Bioscience
Agilent has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.
Tuesday, November 03, 2015
Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
Nonprofit organization offers scientists access to leading-edge technologies.
Saturday, October 31, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent to Acquire Seahorse Bioscience
Acquisition complements Agilent’s market-leading separations and mass spectrometry solutions, expands pharma offerings.
Thursday, September 10, 2015
Scientific News
Adoption of Three Dimensional Culture Models May Save Lives
Physiologically relevant cell models can detect chronic hepatotoxicity early in the drug discovery process.
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Diverse Fungi Secrete Similar Suite of Decomposition Enzymes
A recent study reveals different fungal species secrete a rich set of enzymes that share similar functions, despite species-specific differences in the amino acid sequences of these enzymes.
Lower Mortality with Polyunsaturated Fat
In a study from Uppsala University the fatty acid linoleic acid (Omega 6) in subcutaneous adipose tissue was linked to lower mortality among older men followed over a 15-year period.
'Missing Evolutionary Link' of a Widely Used Natural Drug Source Found
A well-known family of natural compounds, called “terpenoids,” have a curious evolutionary origin. In particular, one question relevant to future drug discovery has puzzled scientists: exactly how does Nature make these molecules?
‘Lead Actors’ in Immune Cell Development
A new study, led by scientists at The Scripps Research Institute (TSRI), reveals a surprising twist in immune biology.
Probing How CRISPR-Cas9 Works
New study in Journal of Cell Biology examines DNA targeting dynamics in live cells.
Microbiome Impacts Tissue Repair, Regeneration
Researchers at the Stowers Institute have established a definitive link between the makeup of the microbiome, the host immune response, and an organism’s ability to heal itself.
Diagnosing Tumors of Unknown Origin
EPICUP® test is a tool that helps to identify up to 87% of cancers of unknown origin (COD).
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!